Kiniksa Pharmaceuticals International reports mixed Q4 results; introduces FY26 outlook
Source: SeekingAlpha
2026-02-24 07:33:19 ET
More on Kiniksa Pharmaceuticals International, plc
- Kiniksa: Arcalyst Is The Engine, But KPL-387 Is The Accelerator
- Kiniksa Pharmaceuticals International, plc (KNSA) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Kiniksa Pharmaceuticals International, plc (KNSA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Kiniksa Pharmaceuticals International, plc Q4 2025 Earnings Preview
- Kiniksa Pharmaceuticals sees ARCALYST net product revenue between $900M-$920M for 2026
Read the full article on Seeking Alpha
For further details see:
Kiniksa Pharmaceuticals International reports mixed Q4 results; introduces FY26 outlook
Kiniksa Pharmaceuticals Ltd.
NASDAQ: KNSA
KNSA Trading
-1.11% G/L:
$46.1702 Last:
108,304 Volume:
$46.92 Open:
KNSA Latest News
February 25, 2026 04:01:00 pm
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference
February 24, 2026 07:30:00 am
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
KNSA Stock Data
$3,390,723,279
40,262,707
0.03%
71
N/A
Biotechnology & Life Sciences
Healthcare
BM
London
